Journal of Leukocyte Biology BioLegend: Treg, Th17, Stem Cell
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published online as doi:10.1189/jlb.0504278 on September 2, 2004

Published online before print September 2, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0504278v1
76/6/1214    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sconocchia, G.
Right arrow Articles by Barrett, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sconocchia, G.
Right arrow Articles by Barrett, A. J.
(Journal of Leukocyte Biology. 2004;76:1214-1219.)
© 2004 by Society for Leukocyte Biology

G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte

Giuseppe Sconocchia1, Hiroshi Fujiwara, Katayoun Rezvani, Keyvan Keyvanfar, Frank El Ouriaghli, Matthias Grube, Jos Melenhorst, Nancy Hensel and A. John Barrett

Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland

1 Correspondence: Hematology Branch, Hematopoietic Stem Cell Transplantation Section, National Heart Lung and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda MD 20892-0001. E-mail: giuseppe.sconocchia{at}roswellpark.org

To study the early stages of development from stem cells of the CD56+ cell population [which includes natural killer (NK) cells], granulocyte-colony stimulating factor-mobilized peripheral blood CD34+ cells from healthy donors were sorted to >99% purity and cultured in the presence of stem cell factor and interleukin (IL)-2. After 3 weeks in culture, the majority of cells acquired CD33, with or without human leukocyte antigen-DR and CD14. In 20 stem cell donors tested, 8.7 ± 8.8% of cells were CD56+. Two major CD56+ subsets were identified: CD56bright, mainly CD33– cells (7±10%, n=11) with large, granular lymphocyte morphology, and CD56dim, mainly CD33+ (2.5±2, n=11) cells with macrophage morphology. The CD56bright population had cytoplasmic granzyme A but lacked killer inhibitory receptor, suggesting they were immature NK cells. The CD56dim, CD33+, population lacked NK markers. They may represent a minor subset of normal monocytes at a developmental stage comparable with the rare CD56+ CD33+ hybrid myeloid/NK cell leukemia. Consistent with a monocyte nature, CD56dimCD33+ proliferated and produced a variety of cytokines upon lipopolysaccharide stimulation, including IL-8, IL-6, monocyte chemoattractant protein-1, and macrophage-derived chemokine but not interferon-{gamma}. In a short-term cytotoxicity assay, they failed to kill but powerfully inhibited the proliferation of the NK-resistant cell line P815. The generation of CD56+ cells was negatively regulated by hyaluronic acid and IL-4, indicating that extracellular matrix may play an important role in the commitment of CD34+ cells into CD56 myeloid and lymphoid lineages.

Key Words: NK cells • monocytes/macrophages • cellular proliferation • cellular differentiation




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
M. Stec, K. Weglarczyk, J. Baran, E. Zuba, B. Mytar, J. Pryjma, and M. Zembala
Expansion and differentiation of CD14+CD16 and CD14++CD16+ human monocyte subsets from cord blood CD34+ hematopoietic progenitors
J. Leukoc. Biol., September 1, 2007; 82(3): 594 - 602.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Sconocchia, D. Del Principe, and A. J. Barrett
CD16low/negative Tumor-Infiltrating Lymphocyte: Lymphoid or Myeloid in Origin?
Clin. Cancer Res., March 1, 2007; 13(5): 1620 - 1620.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Society for Leukocyte Biology.